Omeros (NASDAQ:OMER) Given “Buy” Rating at D. Boral Capital

Omeros (NASDAQ:OMER)‘s stock had its “buy” rating reiterated by stock analysts at D. Boral Capital in a research report issued on Tuesday,Benzinga reports. They presently have a $36.00 target price on the biopharmaceutical company’s stock. D. Boral Capital’s price objective points to a potential upside of 337.96% from the company’s previous close.

A number of other equities research analysts also recently weighed in on OMER. StockNews.com downgraded Omeros from a “hold” rating to a “sell” rating in a research report on Friday, March 21st. Needham & Company LLC reaffirmed a “hold” rating on shares of Omeros in a report on Friday, January 17th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $22.50.

Omeros Stock Performance

NASDAQ:OMER opened at $8.22 on Tuesday. The firm has a 50-day simple moving average of $8.66 and a 200-day simple moving average of $7.58. Omeros has a one year low of $2.61 and a one year high of $13.60. The firm has a market cap of $476.35 million, a P/E ratio of -3.56 and a beta of 2.03.

Omeros (NASDAQ:OMER) last issued its quarterly earnings data on Monday, March 31st. The biopharmaceutical company reported ($0.54) EPS for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.17. During the same quarter in the prior year, the company posted ($0.15) earnings per share. On average, research analysts predict that Omeros will post -3.09 EPS for the current fiscal year.

Hedge Funds Weigh In On Omeros

Several hedge funds and other institutional investors have recently modified their holdings of OMER. Truvestments Capital LLC increased its stake in Omeros by 116.5% during the 4th quarter. Truvestments Capital LLC now owns 3,102 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 1,669 shares in the last quarter. Tower Research Capital LLC TRC grew its holdings in shares of Omeros by 79.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 4,467 shares of the biopharmaceutical company’s stock valued at $44,000 after buying an additional 1,972 shares during the last quarter. Quantbot Technologies LP acquired a new position in shares of Omeros in the 4th quarter valued at $46,000. BNP Paribas Financial Markets increased its position in shares of Omeros by 130.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 12,388 shares of the biopharmaceutical company’s stock valued at $49,000 after acquiring an additional 7,016 shares during the period. Finally, Picton Mahoney Asset Management raised its stake in Omeros by 692.5% in the 4th quarter. Picton Mahoney Asset Management now owns 5,040 shares of the biopharmaceutical company’s stock worth $50,000 after acquiring an additional 4,404 shares during the last quarter. 48.79% of the stock is owned by hedge funds and other institutional investors.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.